Eli Lilly and Company

ProQR Announces First Quarter 2024 Operating and Financial Results

Retrieved on: 
Donnerstag, Mai 9, 2024
EON, Trident, Annual general meeting, Research, Partnership, Doctor of Philosophy, Webcast, Biomarker, Knowledge, Cholestasis, NTCP, RNA editing, Oncology, European Patent Convention, Oligonucleotide, Serum, Lilly, Eli Lilly and Company, Ribose, Pseudouridine, Poster, Alnylam Pharmaceuticals, Eli Lilly, RNA, Exercise, NHP, Clinical trial, ProQR, ADAR, B4GALT1, Adenosine, EDT, Science, Patent, Patient, Liver, Eon, Metabolism, Uridine, Q&A, Pharmaceutical industry

(Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today reported its financial and operating results for the first quarter ended March 31, 2024, and provided a business update.

Key Points: 
  • (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today reported its financial and operating results for the first quarter ended March 31, 2024, and provided a business update.
  • At March 31, 2024, ProQR held cash and cash equivalents and short term financial assets of €102.7 million, compared to €118.9 million cash and cash equivalents at December 31, 2023.
  • General and administrative costs were €3.5 million for the quarter ended March 31, 2024 compared to €4.0 million for the same period last year.
  • For further financial information for the period ended March 31, 2024, please refer to the Q1 financial report filing.

Merus Announces Financial Results for the First Quarter 2024 and Provides Business Update

Retrieved on: 
Mittwoch, Mai 8, 2024
FDA, CFO, Research, CRC, Partnership, PDAC, ASCO, CD137, AACR, Biomarker, EGFR, Lung cancer, Non-small-cell lung cancer, Drug design, Illinois State University, HER2, Food, Bristol Myers Squibb, Patent, Eli Lilly and Company, BLA, NRG1, Therapy, NSCLC, PYC, Safety, Cetuximab, Pembrolizumab, Marketing, Clinical trial, CD3, MET, HNSCC, Gilead Sciences, Betta, Epitope, Biologics license application, Patient, Antigen, Head, Pharmaceutical industry

Merus plans to provide updated efficacy, durability and safety data of this cohort in the second half of 2024.

Key Points: 
  • Merus plans to provide updated efficacy, durability and safety data of this cohort in the second half of 2024.
  • In 2024, Merus is planning to initiate the evaluation of petosemtamab with standard chemotherapy in 2L CRC.
  • During the first quarter of 2024, Merus achieved a milestone of $1 million for candidate nomination and expects to receive payment in the second quarter of 2024.
  • In March 2024, Merus and Gilead Sciences announced a collaboration to discover novel antibody based trispecific T-cell engagers using Merus’ patented Triclonics® platform.

IMUNON Appoints Director Dr. Stacy R. Lindborg as President and CEO

Retrieved on: 
Mittwoch, Mai 8, 2024
Baylor University, SPA, Ovarian cancer, Food, Statistics, Eli Lilly, Brainstorm, Science, Psychology, Patient, American Statistical Association, ALS, Eli Lilly and Company, Biogen, Therapy, COVID-19, Growth, International Biometric Society, Management

LAWRENCEVILLE, N.J., May 08, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing non-viral DNA-mediated immunotherapy and next-generation vaccines, today announced the appointment of Stacy R. Lindborg, Ph.D. as President and Chief Executive Officer, effective May 13, 2024. Dr. Lindborg has served on IMUNON’s board of directors since 2021.

Key Points: 
  • Dr. Lindborg assumes the leadership of IMUNON at a pivotal time.
  • Lindborg is uniquely qualified to take the reins as IMUNON’s President and CEO, bringing a track record of success in virtually every aspect of the work before the company,” said Michael H. Tardugno, IMUNON’s executive chairman.
  • We have benefited significantly from her counsel as a director, where she has played an integral role in establishing our strategic priorities.
  • Dr. Lindborg previously was Vice President & Global Analytics and Data Sciences Head, responsible for R&D and marketed products at Biogen.

Amylyx Pharmaceuticals Reports First Quarter 2024 Financial Results

Retrieved on: 
Donnerstag, Mai 9, 2024
Research, FDA, Neurology, Clinical Trials, Biotechnology, Health, Pharmaceutical, Other Science, Science, Investment, Webcast, IND, WFS1, TDP43, AMX0035, Diabetes, Samuel, CSF, Biomarker, Astellas Pharma, Disclosure, Brain, Food, Amylyx Pharmaceuticals, Endoplasmic reticulum, Health Canada, Tauopathy, ALS, Eli Lilly and Company, FCCP, Medication, Merck, Cerebrospinal fluid, Safety, PB, Neurological disorder, Genetic linkage, Week, Wolfram syndrome, C-peptide, DSM-IV codes, Drug development, Clinical trial, Walking, Division, MD, Patient, Disease, Regulation Fair Disclosure, Principal, Regulation, PGIC, Metabolism, Interim, FACP, Pharmaceutical industry

Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today reported financial results for the first quarter ended March 31, 2024.

Key Points: 
  • Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today reported financial results for the first quarter ended March 31, 2024.
  • This decision was informed by topline PHOENIX trial results, engagement with regulatory authorities, and discussions with the ALS community.
  • Amylyx anticipates reporting topline data from all 12 participants at Week 24 in the fall of 2024.
  • Amylyx’ management team will host a conference call and webcast today, May 9, 2024, at 8:00 a.m.

Redwire Pioneering Biopharma Production in Space by Successfully Bioprinting Live Human Heart Tissue and Delivering Second Batch of PIL-BOX Pharmaceutical Crystal Experiments

Retrieved on: 
Mittwoch, Mai 8, 2024
Other Health, General Health, Pharmaceutical, Technology, Satellite, Science, Cardiology, Aerospace, Other Technology, Manufacturing, Other Science, Health, BFF, Blood, RDW, ISS, Corporation, International Space Station, Eli Lilly and Company, Research, Life, Patient, Lilly, Multimedia, Drug discovery, PIL

The tissue sample returned to Earth along with the second batch of pharmaceutical crystal experiments from Redwire’s PIL-BOX platform.

Key Points: 
  • The tissue sample returned to Earth along with the second batch of pharmaceutical crystal experiments from Redwire’s PIL-BOX platform.
  • View the full release here: https://www.businesswire.com/news/home/20240507667003/en/
    Live human heart tissue bioprinted with Redwire's BioFabrication Facility onboard the International Space Station.
  • Redwire’s second batch of returned PIL-BOX experiments comprised of 36 crystal experiments, which included various crystal molecules designed for pharmaceutical use, with antiviral, antifungal, and antiseizure applications.
  • Redwire has developed 20 research facilities for crewed spacecraft, with 10 currently aboard the ISS supporting world-leading research and manufacturing missions.

TIME Reveals the Inaugural TIME100 Health List of the World's Most Influential People in Health

Retrieved on: 
Donnerstag, Mai 2, 2024
Cancer, EVP, CDC, Bionics, Eli Lilly, Medicaid, Migrant Clinicians Network, Podcast, TIME, Future, Novo Nordisk, HEALTH, Medicare, Eli Lilly and Company, Apple, Letter, AstraZeneca, Woman, Northwell Health

--See the complete 2024 TIME100 Health list: time.com/time100health --See the TIME100 Health cover featuring an illustration by Peter Greenwood for TIME: https://bit.ly/3Uojcso 

Key Points: 
  • NEW YORK, May 2, 2024 /PRNewswire/ -- Today, TIME reveals the inaugural TIME100 Health list recognizing the 100 most influential individuals in health.
  • Health innovation, like this list, reflects humanity at its best: people using all their resourcefulness and ingenuity to help one another live better….
  • The youngest individual recognized on the inaugural TIME100 Health list is 28-year-old Dale Whelehan, CEO of Four Day Week Global.
  • See the full 2024 TIME100 Health list here: time.com/time100health
    TIME will convene the TIME100 Impact Dinner: Leaders Shaping the Future of Health to spotlight an array of leaders including those featured on the new TIME100 Health list of 100 individuals on May 13th in New York City.

As Early-Onset Breast Cancer Cases Soar in North America and EU, Biotech Ramps Up Response

Retrieved on: 
Dienstag, April 30, 2024
FDA, Pancreatic cancer, News, Breast, Fulvestrant, Fast track (FDA), ONC, MBC, PFE, Classification, ICE3, Breast cancer, Paclitaxel, Learning, Kidney, Woman, Economics, Hand, Traction, TSX, Optimism, Eli Lilly and Company, Patient satisfaction, Proteolysis, Freezing, Survival, NEO, Marketing, Clinical trial, CDK, University, Progression-free survival, Recurrence, Disease, Chimera, Patient, Liver, Neoplasm, Type, Growth, Pharmaceutical industry

VANCOUVER, BC, April 30, 2024 /PRNewswire/ -- USA News Group – An alarming rise in early-onset cancers has medical experts very concerned, as cancer cases in younger people are rising sharply. In particular, a surge in cases of breast cancer is being witnessed in Canada, the USA, and the EU, with extra concern to patients thought to be in remission contracting breast cancer a second time, according to a new study from the University of Cambridge. However, there's still optimism towards new treatments, and significant growth of 9.3% CAGR in the metastatic HR+/HER2- breast cancer market through 2032 has treatment developers working harder to make gains for patients. Among the biotech companies currently making strides are Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), IceCure Medical Ltd (NASDAQ: ICCM), Atossa Therapeutics, Inc. (NASDAQ: ATOS), Arvinas, Inc. (NASDAQ: ARVN), and Pfizer Inc. (NYSE: PFE) (NEO: PFE).

Key Points: 
  • Recently, Oncolytics announced that they had submitted a Type C meeting request to the FDA to discuss a forthcoming trial for pelareorep aimed at treating HR+/HER2- metastatic breast cancer (mBC) patients.
  • "A key focus for Oncolytics in 2024 is defining the regulatory path for pelareorep in breast cancer treatment," said Matt Coffey, President and CEO of Oncolytics.
  • "We are optimistic that pelareorep, in combination with paclitaxel, could significantly enhance clinical outcomes for patients with HR+/HER2- metastatic breast cancer.
  • The company looks forward to meeting with the FDA in Q2 2024 to finalize the trial design and goals for using pelareorep in treating metastatic breast cancer.

As Early-Onset Breast Cancer Cases Soar in North America and EU, Biotech Ramps Up Response

Retrieved on: 
Dienstag, April 30, 2024
FDA, Pancreatic cancer, News, Breast, Fulvestrant, Fast track (FDA), ONC, MBC, PFE, Classification, ICE3, Breast cancer, Paclitaxel, Learning, Kidney, Woman, Economics, Hand, Traction, TSX, Optimism, Eli Lilly and Company, Patient satisfaction, Proteolysis, Freezing, Survival, NEO, Marketing, Clinical trial, CDK, University, Progression-free survival, Recurrence, Disease, Chimera, Patient, Liver, Neoplasm, Type, Growth, Pharmaceutical industry

VANCOUVER, BC, April 30, 2024 /PRNewswire/ -- USA News Group – An alarming rise in early-onset cancers has medical experts very concerned, as cancer cases in younger people are rising sharply. In particular, a surge in cases of breast cancer is being witnessed in Canada, the USA, and the EU, with extra concern to patients thought to be in remission contracting breast cancer a second time, according to a new study from the University of Cambridge. However, there's still optimism towards new treatments, and significant growth of 9.3% CAGR in the metastatic HR+/HER2- breast cancer market through 2032 has treatment developers working harder to make gains for patients. Among the biotech companies currently making strides are Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), IceCure Medical Ltd (NASDAQ: ICCM), Atossa Therapeutics, Inc. (NASDAQ: ATOS), Arvinas, Inc. (NASDAQ: ARVN), and Pfizer Inc. (NYSE: PFE) (NEO: PFE).

Key Points: 
  • Recently, Oncolytics announced that they had submitted a Type C meeting request to the FDA to discuss a forthcoming trial for pelareorep aimed at treating HR+/HER2- metastatic breast cancer (mBC) patients.
  • "A key focus for Oncolytics in 2024 is defining the regulatory path for pelareorep in breast cancer treatment," said Matt Coffey, President and CEO of Oncolytics.
  • "We are optimistic that pelareorep, in combination with paclitaxel, could significantly enhance clinical outcomes for patients with HR+/HER2- metastatic breast cancer.
  • The company looks forward to meeting with the FDA in Q2 2024 to finalize the trial design and goals for using pelareorep in treating metastatic breast cancer.

American Kidney Fund Launches National Kidney Health Equity Media Campaign

Retrieved on: 
Donnerstag, April 25, 2024
Kidney disease, University, Radio, Kidney failure, Trustee, National TV, American Kidney Fund, Pancreas transplantation, Dialysis, AKF, Contextual advertising, Eli Lilly and Company, All, Therapy, PSAS, AstraZeneca, Prevalence, Vertex Pharmaceuticals, Pharmaceutical industry

ROCKVILLE, Md., April 25, 2024 (GLOBE NEWSWIRE) -- As part of its longstanding commitment to kidney health equity, the American Kidney Fund (AKF) has launched a national media campaign aimed at bringing greater awareness of kidney disease within Black and Hispanic/Latino communities, the two groups most disproportionately affected by kidney failure in the United States.

Key Points: 
  • ROCKVILLE, Md., April 25, 2024 (GLOBE NEWSWIRE) -- As part of its longstanding commitment to kidney health equity, the American Kidney Fund (AKF) has launched a national media campaign aimed at bringing greater awareness of kidney disease within Black and Hispanic/Latino communities, the two groups most disproportionately affected by kidney failure in the United States.
  • A central piece of AKF’s Kidney Health for All™ program, this yearlong campaign focuses on prevention and disease management and will include national TV, streaming and radio PSAs, digital advertising, video in primary care doctor’s offices, and ads on billboards and public transit in metropolitan areas with high rates of kidney disease.
  • “Our message is clear: ‘We don’t just believe in Kidney Health for All – we work to achieve it,’” said LaVarne A. Burton, AKF President and CEO.
  • “Through these awareness efforts, we hope to educate Americans, particularly those in communities where rates of end-stage kidney disease are high, that dialysis is not evitable.

Recludix Pharma Announces the Appointment of Dr. Ajay Nirula, Accomplished Pharma Executive and Immunology Expert, as Executive Vice President and Head of Research and Development, and Strengthens Scientific Advisory Board with the Addition of Dr. Adrian

Retrieved on: 
Dienstag, April 23, 2024
Nature Immunology, School, University, Cancer, Biogen, COVID, SAB, Remdesivir, Medical school, Merck & Co., Los Angeles School, Eli Lilly, Amgen, Developmental Biology (journal), Inflammation, STAT3, Molecular biology, Yale University, Research, Lupus, STAT6, Growth, SH2, JAMA, Eli Lilly and Company, UCSF, Patient, Doctor of Pharmacy, Rheumatoid arthritis, Psoriasis, Vasculitis, Morphic, Lilly, Multiple sclerosis, Drug discovery, SAN, Division, Investigational New Drug, Science and nature, Pharmaceutical industry

“We are thrilled to welcome Ajay and Adrian to Recludix,” said Nancy Whiting, PharmD, CEO of Recludix. “Ajay joins us from Eli Lilly with over two decades of executive leadership experience spanning all stages of drug discovery and development. He has extensive expertise in immunology and has led the advancement and strategic oversight of deep pipelines with more than ten product candidates reaching the clinic during his Lilly tenure. At Recludix, we have a robust pipeline of validated targets, starting with our two lead programs -- oral and reversible inhibitors of STAT3 and STAT6. Additionally, our proprietary drug discovery platform has enabled us to drug many other exciting previously undruggable SH2 domain targets. Ajay’s deep experience leading a broad discovery and development immunology portfolio – both internally and through strategic partnerships -- is ideally suited to capitalize on the many opportunities at Recludix.”

Key Points: 
  • “We are thrilled to welcome Ajay and Adrian to Recludix,” said Nancy Whiting, PharmD, CEO of Recludix.
  • “Ajay joins us from Eli Lilly with over two decades of executive leadership experience spanning all stages of drug discovery and development.
  • At Recludix, we have a robust pipeline of validated targets, starting with our two lead programs -- oral and reversible inhibitors of STAT3 and STAT6.
  • Additionally, our proprietary drug discovery platform has enabled us to drug many other exciting previously undruggable SH2 domain targets.